Invivyd, Inc. (NASDAQ: IVVD) has reported its preliminary fourth-quarter (Q4) 2025 revenue and recent business highlights, showcasing significant growth and strategic advancements. The company's preliminary Q4 2025 revenue for its Pemgarda® (Pemivibart) net product is $17.2 million, representing a noteworthy 25% increase year-over-year and a substantial 31% increase quarter-over-quarter. This growth is indicative of the company's strong commercial execution and the enduring demand for monoclonal antibody prophylaxis, despite declining COVID vaccination trends.
Furthermore, the company has bolstered its financial position with an ending 2025 cash and cash equivalents of $226.7 million, following successful financing transactions that raised over $200 million in the second half of 2025.
Invivyd has also made significant strides in its clinical and regulatory developments, including the initiation of the Declaration Phase 3 pivotal clinical trial for Vyd2311, a vaccine-alternative antibody aimed at preventing COVID. The company has received fast track designation for Vyd2311 from the U.S. Food and Drug Administration (FDA), enabling an expedited development and review process. Top-line data for the trial is expected in mid-2026.
Moreover, the company has expanded its pipeline with the nomination of a potential best-in-class respiratory syncytial virus (RSV) antibody candidate, Vby329, and has initiated efforts to select a preclinical measles monoclonal antibody candidate in the first half of 2026.
In terms of financial updates, Invivyd's preliminary Q4 2025 Pemgarda net product revenue of $17.2 million represents a 25% increase over Q4 2024 net product revenue of $13.8 million and a 31% increase over Q3 2025 net product revenue of $13.1 million.
The company has also strengthened its balance sheet with an anticipated 2025 ending cash and cash equivalents of $226.7 million, and a total of 281,987,033 shares of common stock outstanding as of December 31, 2025, excluding pre-funded warrants.
These developments reflect Invivyd's commitment to advancing its pipeline of monoclonal antibodies and its readiness to support pivotal clinical trials and potential commercial launches. The company's strategic initiatives and financial growth position it for continued success in addressing critical infectious diseases and developing essential alternatives and complements to vaccination, driving substantial medical and shareholder value creation.
Invivyd's strong financial performance and significant advancements in its pipeline underscore its dedication to delivering protection from serious viral infectious diseases and its potential to establish new standards of care for COVID prophylaxis. As a result of these announcements, the company's shares have moved -4.27% on the market, and are now trading at a price of $2.69. Check out the company's full 8-K submission here.
